Fabian Proft
YOU?
Author Swipe
View article: Frequency of difficult-to-manage and treatment-refractory axial SpA: insights from the German RABBIT-SpA register using recent ASAS definitions
Frequency of difficult-to-manage and treatment-refractory axial SpA: insights from the German RABBIT-SpA register using recent ASAS definitions Open
Objectives To determine the frequency of axial spondyloarthritis (axSpA) patients fulfilling the recently proposed Assessment of SpondyloArthritis International Society (ASAS) definitions for difficult-to-manage (D2M) and treatment-refract…
View article: The impact of non‐steroidal anti‐inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: 10‐year results from an inception cohort
The impact of non‐steroidal anti‐inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: 10‐year results from an inception cohort Open
Objectives This study aims to investigate the impact of non‐steroidal anti‐inflammatory drug (NSAID) intake on radiographic spinal progression in axial spondyloarthritis (axSpA), considering different NSAID types (COX‐2 inhibitors [COX2i] …
View article: Virtual non-calcium imaging to detect bone marrow edema in patients with arthritis: a feasibility study with MRI as standard of reference
Virtual non-calcium imaging to detect bone marrow edema in patients with arthritis: a feasibility study with MRI as standard of reference Open
VNCa imaging showed excellent specificity, albeit only moderate sensitivity for detecting BME in patients with suspected hand arthritis. These results underscore the clinical utility of DECT for arthritis imaging, adding to known strengths…
View article: Complement system activation is associated with spinal radiographic progression in axial spondyloarthritis after 2 years of follow-up: findings from the CONSUL RCT
Complement system activation is associated with spinal radiographic progression in axial spondyloarthritis after 2 years of follow-up: findings from the CONSUL RCT Open
Objective To investigate complement system activation and complement protein levels in relation to radiographic progression in axial spondyloarthritis (axSpA) within a longitudinal randomised controlled trial (RCT) of radiographic axSpA pa…
View article: Orthopaedic physicians’ awareness, diagnostic challenges and referral barriers in axial spondyloarthritis: insights from a nationwide survey in Germany
Orthopaedic physicians’ awareness, diagnostic challenges and referral barriers in axial spondyloarthritis: insights from a nationwide survey in Germany Open
Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, potentially leading to pain, stiffness and disability. Despite diagnostic advances, delays persist. Orthopae…
View article: Beyond inflammation: the molecular basis of bone remodeling in axial spondyloarthritis and psoriatic arthritis
Beyond inflammation: the molecular basis of bone remodeling in axial spondyloarthritis and psoriatic arthritis Open
Spondyloarthritis (SpA) encompasses a group of chronic inflammatory diseases with overlapping genetic, clinical, and radiographic features. Axial spondyloarthritis (axSpA), a subset of SpA, predominantly involves the sacroiliac joints and …
View article: Bimekizumab Maintained Stringent Clinical Responses Over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Bimekizumab Maintained Stringent Clinical Responses Over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies Open
Objectives To assess the maintenance of response to bimekizumab (BKZ) among patients (pts) across the full disease spectrum of axial spondyloarthritis (axSpA) over 2 years in the open-label extension (OLE) of BE MOBILE 1 and 2. Methods BE …
View article: Longitudinal association of early axial spondyloarthritis status at the time of diagnosis with disease activity over time: 10-year results from the GESPIC cohort
Longitudinal association of early axial spondyloarthritis status at the time of diagnosis with disease activity over time: 10-year results from the GESPIC cohort Open
Objective Recently, the definition for ‘early axial spondyloarthritis (axSpA)’ was developed by the Assessment of SpondyloArthritis international Society (ASAS), including ≤2 years of axial symptoms as a key element. The aim of this study …
View article: Similarities and differences: disentangling the intersection between axial psoriatic arthritis and axial spondyloarthritis
Similarities and differences: disentangling the intersection between axial psoriatic arthritis and axial spondyloarthritis Open
Spondyloarthritis is a group of chronic inflammatory diseases that includes axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). AxSpA primarily affects the axial skeleton, manifesting with hallmark features such as inflammatory …
View article: Clinical Impact of Multiparametric Contrast‐Enhanced Dual‐Energy Computed Tomography in Arthritis Imaging: A Prospective Single‐Center Study
Clinical Impact of Multiparametric Contrast‐Enhanced Dual‐Energy Computed Tomography in Arthritis Imaging: A Prospective Single‐Center Study Open
Objective We aimed to evaluate the influence of contrast‐enhanced dual‐energy computed tomography (CE‐DECT) in detecting and differentiating rheumatic joint diseases of the hand. Methods In this prospective study, patients with suspected a…
View article: POS0665 APREMILAST IMPROVES PATIENT-REPORTED PAIN REGARDLESS OF SEX AND AGE IN EARLY OLIGOARTICULAR PSORIATIC ARTHRITIS: A POST-HOC ANALYSIS FROM FOREMOST
POS0665 APREMILAST IMPROVES PATIENT-REPORTED PAIN REGARDLESS OF SEX AND AGE IN EARLY OLIGOARTICULAR PSORIATIC ARTHRITIS: A POST-HOC ANALYSIS FROM FOREMOST Open
View article: POS0105 DUAL INHIBITION OF IL-17A AND IL-17F WITH BIMEKIZUMAB DEMONSTRATED LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: FINAL 3-YEAR RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION
POS0105 DUAL INHIBITION OF IL-17A AND IL-17F WITH BIMEKIZUMAB DEMONSTRATED LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: FINAL 3-YEAR RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION Open
View article: OP0254 MICROBIOTA AND CLINICAL RESPONSES TO BIOLOGICAL TREATMENT IN AXIAL SPONDYLOARTHRITIS: INSIGHTS FROM 2 YEAR FOLLOW UP OF THE GESPIC COHORT
OP0254 MICROBIOTA AND CLINICAL RESPONSES TO BIOLOGICAL TREATMENT IN AXIAL SPONDYLOARTHRITIS: INSIGHTS FROM 2 YEAR FOLLOW UP OF THE GESPIC COHORT Open
View article: OP0175 ESTABLISHING DEFINITIONS FOR DIFFICULT-TO-TREAT PSORIATIC ARTHRITIS (D2T-PsA) AND COMPLEX-TO-MANAGE PSORIATIC ARTHRITIS (C2M-PsA): INSIGHTS FROM THE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA) INITIATIVE
OP0175 ESTABLISHING DEFINITIONS FOR DIFFICULT-TO-TREAT PSORIATIC ARTHRITIS (D2T-PsA) AND COMPLEX-TO-MANAGE PSORIATIC ARTHRITIS (C2M-PsA): INSIGHTS FROM THE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA) INITIATIVE Open
View article: ABS0537 EARLY IMPROVEMENT OF PAIN, LONG-TERM DISEASE CONTROL, AND QUALITY OF LIFE OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB
ABS0537 EARLY IMPROVEMENT OF PAIN, LONG-TERM DISEASE CONTROL, AND QUALITY OF LIFE OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB Open
View article: POS0524 Impact of Psoriasis on Clinical Outcomes, Treatment Responses, and Radiographic Features in Patients with Axial Spondyloarthritis: A 10-Year Analysis from the GESPIC Cohort
POS0524 Impact of Psoriasis on Clinical Outcomes, Treatment Responses, and Radiographic Features in Patients with Axial Spondyloarthritis: A 10-Year Analysis from the GESPIC Cohort Open
View article: POS0231 BIOMARKERS OF GUT EPITHELIAL DAMAGE, MICROBIAL TRANSLOCATION, AND INNATE IMMUNE ACTIVATION CHARACTERIZE PATIENTS WITH AXIAL PSORIATIC ARTHRITIS FROM PSORIASIS PATIENTS: SOLUBLE BIOMARKER ANALYSIS INSIGHTS FROM THE ATTRACT STUDY
POS0231 BIOMARKERS OF GUT EPITHELIAL DAMAGE, MICROBIAL TRANSLOCATION, AND INNATE IMMUNE ACTIVATION CHARACTERIZE PATIENTS WITH AXIAL PSORIATIC ARTHRITIS FROM PSORIASIS PATIENTS: SOLUBLE BIOMARKER ANALYSIS INSIGHTS FROM THE ATTRACT STUDY Open
View article: OP0313 TO X-RAY OR NOT TO X-RAY - PRELIMINARY RESULTS OF A COMPARATIVE STUDY ON FIRST-LINE IMAGING IN SUSPECTED AXIAL SPONDYLOARTHRITIS (axSpA)
OP0313 TO X-RAY OR NOT TO X-RAY - PRELIMINARY RESULTS OF A COMPARATIVE STUDY ON FIRST-LINE IMAGING IN SUSPECTED AXIAL SPONDYLOARTHRITIS (axSpA) Open
View article: OP0100 Early axial spondyloarthritis at inclusion is associated with favorable clinical outcomes after up to 10 years of observation: long-term results from the GESPIC Cohort
OP0100 Early axial spondyloarthritis at inclusion is associated with favorable clinical outcomes after up to 10 years of observation: long-term results from the GESPIC Cohort Open
View article: ABS1148 PERIODONTAL DISEASE IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS
ABS1148 PERIODONTAL DISEASE IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS Open
View article: ABS0543 INTERIM ANALYSIS OF A EUROPEAN REAL-WORLD STUDY ON THE EFFECTIVENESS, PHYSICIAN SATISFACTION, AND PATIENT CHARACTERISTICS IN PSORIATIC ARTHRITIS TREATED WITH BIMEKIZUMAB: INSIGHTS FROM GERMANY, SPAIN, AND THE UNITED KINGDOM
ABS0543 INTERIM ANALYSIS OF A EUROPEAN REAL-WORLD STUDY ON THE EFFECTIVENESS, PHYSICIAN SATISFACTION, AND PATIENT CHARACTERISTICS IN PSORIATIC ARTHRITIS TREATED WITH BIMEKIZUMAB: INSIGHTS FROM GERMANY, SPAIN, AND THE UNITED KINGDOM Open
View article: POS0428 EFFECTS OF SONELOKIMAB, AN IL-17A- AND IL-17F-INHIBITING NANOBODY, ON PATIENT-REPORTED PSORIATIC ARTHRITIS SYMPTOMS AND QUALITY OF LIFE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 ARGO TRIAL
POS0428 EFFECTS OF SONELOKIMAB, AN IL-17A- AND IL-17F-INHIBITING NANOBODY, ON PATIENT-REPORTED PSORIATIC ARTHRITIS SYMPTOMS AND QUALITY OF LIFE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 ARGO TRIAL Open
View article: AI in psoriatic disease (“PsAI”): Current insights and future directions
AI in psoriatic disease (“PsAI”): Current insights and future directions Open
View article: P174 Bimekizumab-treated patients with active psoriatic arthritis showed sustained improvements in pain and fatigue: up to 2-year results from two Phase 3 studies
P174 Bimekizumab-treated patients with active psoriatic arthritis showed sustained improvements in pain and fatigue: up to 2-year results from two Phase 3 studies Open
Background/Aims Bimekizumab (BKZ) has demonstrated sustained improvements in pain and fatigue to 1 year in patients with active PsA. Here, we report assessments of patien-treported pain and fatigue up to 2 years in BKZ-treated PsA patients…
View article: Tofacitinib in early active axial spondyloarthritis: protocol of a randomized double-blind, placebo-controlled, multicenter phase IV study, FASTLANE
Tofacitinib in early active axial spondyloarthritis: protocol of a randomized double-blind, placebo-controlled, multicenter phase IV study, FASTLANE Open
Background: Early treatment initiation is one of the strongest predictors of good treatment response in axial spondyloarthritis (axSpA). Recently, the Assessment in SpondyloArthritis International Society (ASAS) defined early axSpA as a di…
View article: Criteria for the authorisation of specialty training for competence in internal medicine and rheumatology—a position paper of the German Society for Rheumatology and Clinical Immunology
Criteria for the authorisation of specialty training for competence in internal medicine and rheumatology—a position paper of the German Society for Rheumatology and Clinical Immunology Open
The model advanced training regulations define the content of advanced training to achieve the qualification of medical specialist in all specialties and sub-specialties of medicine. As rheumatology is one of the ten specialties for intern…
View article: Unraveling the Challenges of Difficult-to-Treat Spondyloarthritis: SPARTAN 2024 Annual Meeting Proceedings
Unraveling the Challenges of Difficult-to-Treat Spondyloarthritis: SPARTAN 2024 Annual Meeting Proceedings Open
View article: Influence of sacroiliac joint variation on clinical features of axial spondyloarthritis: a comparative analysis
Influence of sacroiliac joint variation on clinical features of axial spondyloarthritis: a comparative analysis Open
Objectives Anatomical variation of the sacroiliac (SI) joints is common and specific variants are associated with erosions and bone marrow oedema on imaging. Our investigation aims to evaluate whether anatomical variations influence the cl…
View article: AI for imaging evaluation in rheumatology: applications of radiomics and computer vision—current status, future prospects and potential challenges
AI for imaging evaluation in rheumatology: applications of radiomics and computer vision—current status, future prospects and potential challenges Open
Inflammatory rheumatic diseases, a diverse group of immune-mediated conditions, are characterized by chronic inflammation that can lead to irreversible damage to joints, bones and organs, posing a significant global health challenge. If le…
View article: Association between resolution of MRI-detected inflammation and improved clinical outcomes in axial spondyloarthritis under long-term anti-TNF therapy
Association between resolution of MRI-detected inflammation and improved clinical outcomes in axial spondyloarthritis under long-term anti-TNF therapy Open
Objectives In this post-hoc analysis of ESTHER trial, we aimed to investigate the longitudinal relationship between inflammation on MRI and the achievement of inactive disease/low disease activity in patients with axial spondyloarthritis (…